- Home
- PRTC vs RGNX Comparison
PRTC vs RGNX Comparison
Compare PRTC & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- RGNX
- Stock Information
- Founded
- PRTC 2015
- RGNX 2008
- Country
- PRTC United States
- RGNX United States
- Employees
- PRTC 90
- RGNX N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PRTC Health Care
- RGNX Health Care
- Exchange
- PRTC Nasdaq
- RGNX Nasdaq
- Market Cap
- PRTC 504.9M
- RGNX 459.1M
- IPO Year
- PRTC N/A
- RGNX 2015
- Fundamental
- Price
- PRTC $20.80
- RGNX $11.19
- Analyst Decision
- PRTC Buy
- RGNX Strong Buy
- Analyst Count
- PRTC 1
- RGNX 11
- Target Price
- PRTC $45.00
- RGNX $37.80
- AVG Volume (30 Days)
- PRTC 3.4K
- RGNX 507.4K
- Earning Date
- PRTC 08-28-2024
- RGNX 11-06-2024
- Dividend Yield
- PRTC N/A
- RGNX N/A
- EPS Growth
- PRTC N/A
- RGNX N/A
- EPS
- PRTC N/A
- RGNX N/A
- Revenue
- PRTC $468,000.00
- RGNX $84,327,000.00
- Revenue This Year
- PRTC N/A
- RGNX $7.85
- Revenue Next Year
- PRTC $139.60
- RGNX $217.02
- P/E Ratio
- PRTC N/A
- RGNX N/A
- Revenue Growth
- PRTC N/A
- RGNX N/A
- 52 Week Low
- PRTC $17.08
- RGNX $8.54
- 52 Week High
- PRTC $34.00
- RGNX $28.80
- Technical
- Relative Strength Index (RSI)
- PRTC 55.95
- RGNX 58.40
- Support Level
- PRTC $20.35
- RGNX $8.54
- Resistance Level
- PRTC $20.95
- RGNX $9.87
- Average True Range (ATR)
- PRTC 0.62
- RGNX 0.52
- MACD
- PRTC 0.10
- RGNX 0.12
- Stochastic Oscillator
- PRTC 75.51
- RGNX 75.14
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.